Amyl nitrates are linked to prolonged bilateral vision loss and retinal damage.

Article

Recreational drugs amyl nitrate and isopropyl nitrate (poppers) are associated with bilateral vision loss and retinal disorders due to damage of the foveal cone outer segments.

Recreational drugs amyl nitrate and isopropyl nitrate (poppers) are associated with bilateral vision loss and retinal disorders due to damage of the foveal cone outer segments, according to a study released by the Archives of Ophthalmology.

A team lead by Dr Isabelle Audo, Clinical Investigation Center, Université Pierre et Marie Curie-Paris, France, conducted a restrospective, observational case series on 6 patients with bilateral vision loss after chronic use of amyl or isopropyl nitrates. The outcome measures included: symptoms, medical history, ophthalmic examination and functional and morphological tests.

All patients examined presented with progressive bilateral vision loss. Two patients experienced central photopsia and initial visual acuities varied from 20/50 to 20/25.

In each patient a bilateral yellow foveal spot was found and was linked to the disruption of the foveal cones' outer segments. After discontinued use of poppers, 4 patients demonstrated significant anatomical and functional improvement.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.